US · GLMD
Galmed Pharmaceuticals Ltd.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Ramat Gan 6578317
- Website
- galmedpharma.com
Price · as of 2024-12-31
$0.57
Market cap 3.35M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $2,637.00 | ||||
| 2014 | $1,666.80 | ||||
| 2015 | $855.54 | ||||
| 2016 | $896.40 | ||||
| 2017 | $1,148.40 | $488.55 | $10.52 | $0.00 | $0.00 |
| 2018 | $1,360.80 | $814.04 | $68.93 | $31.93 | $0.00 |
| 2019 | $910.80 | $415.32 | |||
| 2020 | $630.00 | ||||
| 2021 | $243.00 | ||||
| 2022 | $82.80 | ||||
| 2023 | $4.56 | ||||
| 2024 | $1.89 |
AI valuation
Our deep-learning model estimates Galmed Pharmaceuticals Ltd.'s (GLMD) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.57
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GLMD | Galmed Pharmaceuticals Lt… | $0.57 | 3.35M | — | — | — | — | -0.23 | 0.11 | — | 1.83 | — | 0.11 | 0.00% | — | — | -49.77% | -552.15% | -42.80% | 0.00 | -418.53 | 7.42 | 7.15 | 0.63 | -7302.00% | — | -419.00% | -334.59% | -2.71 | -517.15% | 0.00% | 0.00% | 104.25% | 2.16 | 2.31 | — | -14.90 |
| BDRX | Biodexa Pharmaceuticals P… | $1.08 | 90.59K | +65,720% | — | — | — | -0.25 | 0.17 | — | -0.05 | -0.06 | 0.53 | 0.00% | — | — | -88.14% | -269.10% | -45.25% | 0.09 | — | 1.75 | 0.47 | 0.10 | 40524.00% | -10000.00% | 8388.00% | -924.24% | -2.44 | -397.95% | 0.00% | 0.00% | 0.00% | -0.05 | -0.04 | — | -15.86 |
| BIVI | BioVie Inc. | $1.38 | 10.41M | — | — | — | — | -0.15 | 0.14 | — | 0.86 | — | 0.14 | 0.00% | — | — | -101.64% | 8838.56% | -75.01% | 0.02 | -54.30 | 9.10 | 8.64 | 1.01 | -8341.00% | — | -3192.00% | -740.10% | -8.36 | 9307.74% | 0.00% | 0.00% | 0.00% | 0.81 | 0.77 | — | -24.00 |
| CMMB | Chemomab Therapeutics Ltd… | $1.86 | 11.45M | — | — | — | — | -1.60 | 1.66 | — | -0.61 | — | 1.66 | 0.00% | — | — | -91.77% | 1052.79% | -71.64% | 0.02 | — | 4.98 | 4.51 | 0.41 | -6204.00% | — | -3437.00% | -68.89% | -4.80 | 1104.22% | 0.00% | 0.00% | 0.00% | -0.58 | -0.55 | — | -6.50 |
| ELAB | PMGC Holdings Inc. | $1.19 | 126.21K | +401,467% | +24,631% | — | — | -0.06 | 0.06 | 0.16 | 1.12 | — | 0.10 | 72.84% | -75.65% | -253.14% | -119.12% | -110.26% | -88.07% | 0.00 | -2.54 | 3.36 | 2.22 | 1.25 | -8600.00% | 4407.00% | 2032.00% | -1366.73% | -3.05 | -324.66% | 0.00% | 0.00% | 215.87% | 1.92 | 0.65 | -1.45 | -1.81 |
| INM | InMed Pharmaceuticals Inc… | $0.85 | 1.54M | +1,918% | +653% | — | — | -0.25 | 0.11 | 0.42 | 1.66 | — | 0.13 | 34.53% | -160.20% | -165.14% | -52.84% | -173.20% | -43.65% | 0.06 | -21.22 | 6.99 | 6.27 | 1.94 | -5848.00% | 750.00% | 1103.00% | -377.16% | -3.10 | -169.90% | 0.00% | 0.00% | 311.23% | 1.52 | 1.55 | -2.43 | -10.26 |
| ISPC | iSpecimen Inc. | $0.25 | 1.39M | +15,728% | +124% | — | — | -0.08 | 0.30 | 0.11 | 0.04 | — | -0.50 | 42.93% | -136.99% | -134.51% | -191.51% | -381.28% | -99.31% | 0.09 | -57.84 | 0.62 | 0.58 | 0.12 | -2839.00% | -642.00% | -2115.00% | -830.12% | -1.43 | -249.24% | 0.00% | 0.00% | 0.00% | 0.04 | 0.07 | -0.06 | -14.44 |
| MLEC | Moolec Science S.A. | $13.30 | 9.66M | +7,515% | +24,189,467% | — | — | -0.07 | -0.12 | 0.02 | -3.56 | 0.00 | -0.05 | 34.17% | -3.14% | -33.41% | 376.84% | -11.15% | -93.08% | -3.74 | -0.25 | 0.13 | 0.12 | -3.57 | 897895.00% | 583074.00% | 21733.00% | -393.07% | -0.10 | -32.03% | 0.00% | 0.00% | 12.10% | -23.43 | -8.16 | 0.74 | -0.48 |
| VRAX | Virax Biolabs Group Limit… | $0.23 | 988.66K | +58,899% | +71% | — | +71,836% | -0.50 | 0.53 | 478.92 | 0.14 | — | 0.54 | -838.21% | -97344.76% | -95739.17% | -109.69% | -313.42% | -101.88% | 0.07 | -105.93 | 7.27 | 6.33 | 0.66 | -4196.00% | -9595.00% | -3028.00% | -170.43% | -6.78 | -268.72% | 0.00% | 0.00% | 16.06% | 0.13 | 0.16 | -129.50 | -5.85 |
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
- CEO
- Allen Baharaff
- Employees
- 3
- Beta
- 0.38
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.57) − 1 = — (DCF, example).